Ascletis Seals $100M

Ascletis Inc., which is focused on developing therapeutics for cancer and infectious disease, has inked $100 million in commitments for its Series A round, including a first tranche of $50 million. Hangzhou Binjiang Investment Holding Co. led the round, which included “private entrepreneurs from China and other countries including the United States,” the company said in a written statement. Ascletis is based in both Hangzhou, China, and Research Triangle Park, North Carolina.

North AmericaUSBriefs